FIG 2.

Combined use of T cell–redirecting bispecific antibodies in B-cell precursor acute lymphoblastic leukemia and B-cell non-Hodgkin lymphomas. Ongoing clinical trials (see Tables 2 and 3 for details) are evaluating the therapeutic activity of T cell–redirecting bispecific antibodies used in combination with (A) checkpoint inhibitors; (B) tyrosine kinase inhibitors (TKIs); (C) immunomodulatory drugs (IMIDs); (D) chemotherapy; (E) antibody-drug conjugates (ADCs); and (F) costimulatory bispecific antibodies.